A collagen peptide composition and its efficacy and use in improving immunity

By designing a combination of peptide CPF-1 and marine collagen peptides, monoclonal antibody mAb Senolix, pentagalloglucoside, and Hericium erinaceus polysaccharide, this study activates immune cell signaling pathways, eliminates senescent cells, and enhances antioxidant capacity. This addresses the shortcomings of existing collagen peptide products in immune regulation and anti-aging, achieving significant immune enhancement and anti-aging effects.

CN120607629BActive Publication Date: 2025-12-12GUANGZHOU YIPU BIOTECHNOLOGY CO LTD
4 Cites 0 Cited by

Patent Information

Application Number
CN202510758245.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-06-09
Publication Date
2025-12-12
Estimated Expiration
2045-06-09

AI Technical Summary

Technical Problem

Existing collagen peptide products lack precise design for immune regulation, making it difficult to selectively intervene in specific immune cell subsets or senescent cells. They are also susceptible to protease degradation, have low bioavailability and low transmembrane efficiency, resulting in limited intensity and duration of action.

Method used

A fusion peptide, CPF-1, was designed, comprising a collagen-binding domain, an immunomodulatory domain, and an antimicrobial peptide domain. It combines marine collagen peptides, monoclonal antibody mAb Senolix, pentagalloglucoside (PGG), and Hericium erinaceus polysaccharide to activate immune cell signaling pathways, enhance macrophage function, clear senescent cells, and enhance antioxidant capacity and intestinal immune regulation through targeted delivery and multi-component synergistic effects.

Benefits of technology

It significantly enhances macrophage phagocytic function by 51.6%, efficiently clears senescent cells by 87.3%, strengthens antioxidant capacity by 2.3 times, promotes fibroblast proliferation and collagen synthesis by 189%, restores immune function, reverses the learning and memory abilities of aging model mice, and reduces the proportion of senescent cells in the liver.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application discloses a kind of composition with immunoregulation and anti-aging function and preparation method thereof, and core component is marine collagen peptide, fusion polypeptide CPF-1, targeting senescent cell monoclonal antibody mAb Senolix, five gallate acyl glucose (PGG) and Hericium erinaceus polysaccharide.Fusion polypeptide CPF-1 is designed by domain fusion strategy, with collagen binding, immune activation and antibacterial function;Monoclonal antibody mAb Senolix targets the surface antigen p16^(INK4a) of senescent cell, and removes senescent cell by ADCC effect.The composition significantly improves immune cell activity, promotes collagen synthesis and reduces chronic inflammation through the synergistic effect of multiple components, and shows excellent immunoregulation and anti-aging effect in in vitro cell model and immunosuppressed mouse model, and can be used for developing immune enhancer, anti-aging drug or functional food.
Need to check novelty before this filing date? Find Prior Art